SEC Company Response from Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040) (PHIO) — Sep 28, 2018
Phio Pharmaceuticals Corp. (PHIO) (CIK 0001533040)
Date: Sept. 28, 2018 · CIK: 0001533040 · Accession: 0001683168-18-002883
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-227173
Letter
RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough, MA 01752
(508) 767-3861
September 28, 2018
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Dorrie Yale
Re: RXi Pharmaceuticals Corporation
Registration Statement on Form S-1
Filed August 31, 2018
File No. 333-227173
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, RXi Pharmaceuticals Corporation, a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company (the “Registration Statement”) be accelerated to 5:00 p.m., Eastern Daylight Time, on, September 28, 2018 or as soon thereafter as practicable.
Very truly yours,
RXi Pharmaceuticals Corporation
Show Raw Text
CORRESP 1 filename1.htm RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough, MA 01752 (508) 767-3861 September 28, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attn: Dorrie Yale Re: RXi Pharmaceuticals Corporation Registration Statement on Form S-1 Filed August 31, 2018 File No. 333-227173 Ladies and Gentlemen: Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, RXi Pharmaceuticals Corporation, a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company (the “Registration Statement”) be accelerated to 5:00 p.m., Eastern Daylight Time, on, September 28, 2018 or as soon thereafter as practicable. Very truly yours, RXi Pharmaceuticals Corporation /s/ Geert Cauwenbergh Geert Cauwenbergh President, Chief Executive Officer and acting Chief Financial Officer cc: Ryan A. Murr, Gibson, Dunn & Crutcher LLP